Image via GNW — Germany
Last updated
Boehringer Ingelheim: Product Launch
Phase 3 trial data for obesity drug survodutide shows 19% discontinuation rate due to side effects, indicating potential safety/tolerability issues that may impact market launch strategy
Source: GNW — Germany
The leadership read
Product momentum tends to widen biotech & pharma product and commercial leadership bench strength.
Market context: The wider read — a Talent Market Index of 112.8 (Hot), up 11.4 month-on-month — shows Americas signal flow rising (+2.6pts).
Boehringer Ingelheim: 3 signals in the last 90 days — above the Biotech & Pharma median of 1 across 23 tracked companies; 0.1% of MitchelLake's Americas signal flow; 3 tracked across 18 days.
MitchelLake in this thematic
Also at Boehringer Ingelheim →
More signals across Biotech & Pharma
Product Launch · Americas
Bota Biosciences →Bota Biosciences released Biology Protocol Language (BPL) and BPL-COGEN, a compiler-verified protocol language and generation pipeline for AI-driven biomanufacturing, announced on bioRxiv.
Product Launch · Americas
Neurocrine Biosciences →Neurocrine presented CRENESSITY clinical data at ENDO 2026 demonstrating hormone normalization in classic CAH and two-year cardiometabolic and bone health outcomes in adults.
Product Launch · Americas
Merck & Co., Inc. →Merck presenting oncology strategy with focus on clinical progress and pipeline diversification, indicating new program developments and potential launches
Product Launch · Americas
Thermo Fisher Scientific →Thermo Fisher launched new AI-enabled Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at ASMS Conference, integrating with Olink proteomics and recent AI-focused software acquisitions to strengthen competitive positioning in life sciences tools.
Product Launch · Americas
BridgeBio →BridgeBio submitted NDA to FDA for BBP-418 for LGMD2I/R9 treatment, based on positive Phase 3 FORTIFY trial results showing statistically significant improvements
Ma Activity · Americas
Biogen →Biogen acquired Apellis Pharmaceuticals for $5.6B and subsequently paused or canceled the majority of research programs that came with the acquisition, laying off a small number of employees from Apellis.
Intelligence powered by Autonodal ↗